.Attribute Medication, Published online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized phase 3b/4 DESTINY-Breast12 study, trastuzumab deruxtecan (T-DXd) treatment of clients with HER2+ state-of-the-art breast cancer and also active or dependable human brain metastases presented consistent intracranial task as well as systemic effectiveness of T-DXd.